Pulse Biosciences, Inc. has appointed Jon Skinner as its Chief Financial Officer, effective February 3, 2025. Skinner brings a wealth of experience from his previous roles, including serving as Vice President, FP&A and Investor Relations at Copeland, Vice President, Finance and Corporate Development at Imperative Care, and Vice President, Finance – Interventional Urology at Teleflex.
In connection with his appointment, Pulse Biosciences granted Skinner options to purchase 300,000 shares of the company’s common stock at an exercise price of $20.93 per share, which was the closing price of the company’s common stock on January 31, 2024. These inducement grants are subject to vesting conditions, with half of the option shares vesting over four years and the remaining shares vesting upon the achievement of product revenue and market capitalization milestones for the company, ranging from $2 billion to $5 billion.
Pulse Biosciences is a bioelectric medicine company focused on developing its proprietary CellFX® nsPFA™ technology for the treatment of atrial fibrillation and other select markets. The company is headquartered in Miami, Florida, and maintains an office in Hayward, California. The market has reacted to these announcements by moving the company's shares 5.7% to a price of $21.55. For the full picture, make sure to review Pulse Biosciences's 8-K report.
